TY - JOUR
T1 - Mechanistic insight into hyaluronic acid and platelet-rich plasma-mediated anti-inflammatory and anti-apoptotic activities in osteoarthritic mice
AU - Chiou, Chi Sheng
AU - Wu, Chi Ming
AU - Dubey, Navneet Kumar
AU - Lo, Wen Cheng
AU - Tsai, Feng Chou
AU - Xuan Tung, Tran Dang
AU - Hung, Wei Ching
AU - Hsu, Wei Che
AU - Chen, Wei Hong
AU - Deng, Win Ping
N1 - Funding Information:
We are grateful to Stem Cell Research Center and Cancer Center, Taipei Medical University, Taipei, Taiwan for their research support. The authors would also like to thank Core Facility Center, Office of Research and Development, Taipei Medical University for the technical support of flow cytometry. This research was supported by the following grants and agencies: National Science Council (NSC 99-2628-B-038-010-MY3, 101-2314-B-038-023, 102-2314-B-038-058 and 102-2314-B-038-015), the Department of Health (DOH102-TD-PB-111-NSC009)
Publisher Copyright:
© Chiou et al.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Osteoarthritis (OA) poses a major clinical challenges owing to limited regenerative ability of diseased or traumatized chondrocytes in articular cartilage. Previous studies have determined the individual therapeutic efficacies of hyaluronic acid (HA) and platelet-rich plasma (PRP) on OA; however, the underlying mechanism is still lacking. Therefore, we investigated mechanistic approach of HA+PRP therapy on chondrocyte apoptosis in IL-1β+TNF-α (I+T) treated in vitro OA model, in addition to in vivo anterior cruciate ligament transection-OA mice model. MTT assay showed an enhanced chondrocyte proliferation and viability in HA+PRP-treated group, compared to I+T, I+T/HA, I+T/PRP, I+T/HA+PRP groups. Further, HA+PRP also significantly suppressed ROS, apoptotic cleaved caspase-3 and PARP, p53 and p21 and MMP-1; whereas, cell cycle modulatory proteins including p-ERK, cyclin B1, D1, and E2 were upregulated. The sub-G1 population and TUNEL assay confirmed the higher abundance of healthy chondrocytes in HA+PRP group. A significantly decreased ARS staining in HA+PRP group was also noted, indicating reduced cartilaginous matrix mineralization compared to other groups. Conclusively, compared to HA or PRP, the combined HA+PRP might be a promising therapy for articular cartilage regeneration in osteoarthritic pathology, possibly via augmented anti-inflammatory, anti-oxidative chondrocyte proliferation and inhibited MMP-1 activity and matrix calcification.
AB - Osteoarthritis (OA) poses a major clinical challenges owing to limited regenerative ability of diseased or traumatized chondrocytes in articular cartilage. Previous studies have determined the individual therapeutic efficacies of hyaluronic acid (HA) and platelet-rich plasma (PRP) on OA; however, the underlying mechanism is still lacking. Therefore, we investigated mechanistic approach of HA+PRP therapy on chondrocyte apoptosis in IL-1β+TNF-α (I+T) treated in vitro OA model, in addition to in vivo anterior cruciate ligament transection-OA mice model. MTT assay showed an enhanced chondrocyte proliferation and viability in HA+PRP-treated group, compared to I+T, I+T/HA, I+T/PRP, I+T/HA+PRP groups. Further, HA+PRP also significantly suppressed ROS, apoptotic cleaved caspase-3 and PARP, p53 and p21 and MMP-1; whereas, cell cycle modulatory proteins including p-ERK, cyclin B1, D1, and E2 were upregulated. The sub-G1 population and TUNEL assay confirmed the higher abundance of healthy chondrocytes in HA+PRP group. A significantly decreased ARS staining in HA+PRP group was also noted, indicating reduced cartilaginous matrix mineralization compared to other groups. Conclusively, compared to HA or PRP, the combined HA+PRP might be a promising therapy for articular cartilage regeneration in osteoarthritic pathology, possibly via augmented anti-inflammatory, anti-oxidative chondrocyte proliferation and inhibited MMP-1 activity and matrix calcification.
KW - Apoptosis
KW - Chondrocyte
KW - Hyaluronic acid
KW - Inflammation
KW - Osteoarthritis
KW - Platelet-rich plasma
UR - http://www.scopus.com/inward/record.url?scp=85059329714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059329714&partnerID=8YFLogxK
U2 - 10.18632/aging.101713
DO - 10.18632/aging.101713
M3 - Article
C2 - 30582743
AN - SCOPUS:85059329714
SN - 0002-0966
VL - 10
SP - 4152
EP - 4165
JO - Aging
JF - Aging
IS - 12
ER -